Table 5.
AS clinical trial study of the top 10 most frequently cited articles treatment measures analysis.
| Rank | Title | Intervention Measure | Treatment mode | Duration(W) | Primary outcome measure |
|---|---|---|---|---|---|
| 1 | Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis | Secukinumab vs Placebo | Subcutaneous injection or intravenous loading | 52 | ASAS20 |
| 2 | Efficacy and safety of infliximab in patients with ankylosing spondylitis - Results of a randomized, placebo-controlled trial (ASSERT) | Infliximab vs Placebo | Subcutaneous injection | 24 | ASAS20 |
| 3 | Efficacy and safety of adalimumab in patients with ankylosing spondylitis - Results of a multicenter, randomized, double-blind, placebo-controlled trial | Adalimumab vs Placebo | Subcutaneous injection | 24 | ASAS20 |
| 4 | Recombinant human tumor necrosis factor receptor, (etanercept) for treating ankylosing spondylitis - A randomized, controlled trial | Etanercept vs Placebo | Subcutaneous injection | 24 | ASAS20 |
| 5 | Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system | SASSS vs mSASSS | radiograph | 48 | 1984 Modified New York criteria |
| 6 | Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores | ASDAS | — | 24 | ASAS |
| 7 | Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis - A randomized clinical trial | continuous treatment with NSAIDs vs on-demand treatment with NSAIDs | Subcutaneous injection | 96 | mSASSS |
| 8 | A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study | Infliximab (INX) vs CT-P13(a biosimilar to INX) | Subcutaneous injection | 30 | ASAS20 and ASAS40 |
| 9 | Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial | Secukinumab vs Placebo | Subcutaneous injection | 28 | ASAS20 |
| 10 | Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial | Golimumab vs Placebo | Subcutaneous injection | 24 | ASAS20 |
ASAS, Assessment of Spondyloarthritis International Society; ASAS20,Assessment of Spondyloarthritis International Society 20; ASAS40, Assessment of Spondyloarthritis International Society 40; SASSS, Stoke Ankylosing Spondylitis Spinal Score; mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; ASDAS, Ankylosing Spondylitis Disease Activity Score; NSAIDs, Nonsteroidal antiinflammatory drugs.